Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2025 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2025 Earnings Call Transcript February 26, 2026Crinetics Pharmaceuticals, Inc. beats earnings expectations.
Crinetics Pharmaceuticals Inc. (CRNX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 6,933,098 | $322,735,712 | +21% | 1.52% |
| 2. | Driehaus Capital Richard Driehaus | 6,387,740 | $297,349,297 | -2% | 2.02% |
| 3. | EcoR1 Capital Oleg Nodelman | 4,288,120 | $199,611,986 | 9.06% | |
| 4. | Point72 Asset Management Steve Cohen | 2,337,034 | $108,788,933 | +17% | 0.12% |
| 5. | Paradigm Biocapital Advisors Senai Asefaw | 2,210,774 | $102,911,530 | -14% | 2.63% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.06 | 5,000 | $110,300.00 | 5,000 | 2023-06-08 | Filing | |
| $22.22 | 157,515 | $3,499,983.30 | 5,321,032 | 2022-04-18 | Filing | |
| $19.80 | 1,200,000 | $23,760,000.00 | 5,163,517 | 2021-10-25 | Filing | |
| $16.44 | 304,136 | $4,999,995.84 | 3,963,517 | 2021-04-08 | Filing | |
| $13.10 | 4,000 | $52,400.00 | 4,000 | 2020-12-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $37.77 | 3,961 | $149,606.97 | 112,018 | 2026-03-16 | Filing | |
| $37.11 | 5,950 | $220,804.50 | 115,979 | 2026-03-16 | Filing | |
| $37.77 | 4,241 | $160,182.57 | 137,101 | 2026-03-16 | Filing | |
| $37.11 | 6,371 | $236,427.81 | 141,342 | 2026-03-16 | Filing | |
| $37.77 | 8,785 | $331,809.45 | 404,778 | 2026-03-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,293,775 | $665,375,245 | 0.03% | |
| 2. | 9,135,504 | $425,257,712 | 0.01% | |
| 3. | 8,037,889 | $374,163,733 | 0.07% | |
| 4. | 7,988,548 | $371,866,926 | 0.01% | |
| 5. | 4,440,691 | $206,603,847 | 0.09% |
News See All
Analysts Bullish on Crinetics (CRNX) Amid Positive Clinical Trial for New Drug
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 13 hot stocks to buy with the highest upside potential. On January 30, Stifel raised its price target on Crinetics Pharmaceuticals Inc.
13 Hot Stocks to Buy with the Highest Upside Potential
On average, equities are expected continue to deliver positive results in 2026, this time with greater breadth across sectors, styles, and regions, compared to the other periods of the recent bull market...
Jim Cramer Recently Looked at These 25 Stocks
We're in critical short supply for all sorts of chips that are needed in the data center... It wasn't easy to forecast this boom, I admit, as recently as one year ago.
Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is among the 14 best booming stocks to buy right now.
14 Best Booming Stocks to Buy Right Now
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026.
Crinetics Pharmaceuticals (CRNX) Poised for Transformational Growth in 2026: Piper Sandler
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Piper Sandler reiterated that Crinetics Pharmaceuticals Inc.
15 Best Biotech Stocks to Buy According to Wall Street Analysts
The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain for the S&P 500 over the same period.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q3 2025 Earnings Call Transcript
Operator: Welcome to the Crinetics Pharmaceuticals Third Quarter 2025 Financial Results Conference Call. I would now like to turn the call over to Gayathri Diwakar, Head of Investor Relations.
Cantor Fitzgerald Maintains a Buy Rating on Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best biotech stocks with high potential.
Hedge Fund Resource Center